Medroxyprogesterone acetate and dydrogesterone effect in the treatment of uterine bleeding
Phase 3
- Conditions
- vaginal bleeding.Other abnormal uterine and vaginal bleeding
- Registration Number
- IRCT20140111016161N7
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 176
Inclusion Criteria
Endometrial thickness greater than 5 mm
Simple endometrial hyperplasia
Exclusion Criteria
Endocrine disorders
Anatomical problems;
History of hormone therapy
History of coagulopathy
Contraindication for progestin therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vaginal bleeding. Timepoint: At the beginning of the study (before the intervention) and 3 and 6 months after starting the intervention. Method of measurement: Standard check list designed by the research team.;Endometrium thickness. Timepoint: At the beginning of the study (before the intervention) and 3 and 6 months after starting the intervention. Method of measurement: sonography.;Side effects of treatments. Timepoint: At the beginning of the study (before the intervention) and 3 and 6 months after starting the intervention. Method of measurement: Standard check list designed by the research team.
- Secondary Outcome Measures
Name Time Method